Figure 2.

PHZ administration prevents anti-CD40 antibody induced inflammatory liver disease. C57Bl/6J mice were treated with saline (control) or PHZ (90 mg/kg) at T_0h, 48 h later with anti-CD40 antibody (20 mg/kg) (T_48h). The animals were sacrificed at T_60h for plasma cytokines, at T_78h for liver enzymes, and at T_96h for liver histology. (A) Representative photographs of liver lobes and H&E-stained liver tissue sections. Ischemic infarcts were detected in the anti-CD40 antibody-treated mice (visible as white spots on the liver lobes in the area within the violet dashed line on histology). (B) Plasma concentrations of ALT in C57BL/6J mice after treatment with PHZ and/or anti-CD40 antibody (n = 5). (C) Heatmap displaying color-coded plasma concentrations of IL6, IL12p40, TNFα, CCL2, and CCL5 in C57BL/6J mice after treatment with PHZ or anti-CD40 antibody (n = 4) (yellow=low expression, red=high expression). (D) Heatmap displaying color-coded mRNA expression levels of pro-inflammatory cytokines and Hmox1 from Dynabeads-enriched F4/80 positive liver macrophages in C57BL/6J mice after treatment with PHZ or an anti-CD40 antibody (n = 3) (yellow=low expression, red=high expression). mRNA expression was measured by qRT-PCR. Individual symbols represent one mouse; ****p < 0.0001.